Polysaccharides as therapeutic vehicles in pancreatic cancer
Seema Kumari,
No information about this author
Sujatha Peela,
No information about this author
Ganji Purnachandra Nagaraju
No information about this author
et al.
Drug Discovery Today,
Journal Year:
2025,
Volume and Issue:
unknown, P. 104320 - 104320
Published: Feb. 1, 2025
Language: Английский
Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China
Zuojuan Xiang,
No information about this author
Ling Ma,
No information about this author
Zhengxiong Li
No information about this author
et al.
Frontiers in Pharmacology,
Journal Year:
2024,
Volume and Issue:
15
Published: Dec. 20, 2024
The
phase
III
NAPOLI-3
trial,
which
upgraded
FOLFIRINOX
(leucovorin,
fluorouracil,
irinotecan
and
oxaliplatin)
to
NALIRIFOX
(liposomal
irinotecan,
oxaliplatin,
leucovorin,
fluorouracil),
demonstrated
the
superiority
of
over
GEMNABP
(gemcitabine
nab-paclitaxel)
as
first-line
treatment
for
metastatic
pancreatic
ductal
adenocarcinoma.
purpose
this
study
was
assess
cost-effectiveness
NALIRIFOX,
FOLFIRINOX,
GEMNABP,
simulate
price
liposomal
at
could
achieve
cost-effectiveness.
Language: Английский